Nyrada Half Year Results FY2022
Highlights: • Research and development costs of $1.13M as Nyrada’s lead preclinical programs advance (1H FY2021: $1.05M) • Robust cash… Read more
Highlights: • Research and development costs of $1.13M as Nyrada’s lead preclinical programs advance (1H FY2021: $1.05M) • Robust cash… Read more
Highlights: • Cholesterol-Lowering Program: – Charles River Laboratories appointed to conduct safety pharmacology and toxicology studies in Nyrada’s cholesterol-lowering drug… Read more
This morning Nyrada provided an update on their brain injury program. The company is currently undertaking a pilot study to… Read more
Nyrada (ASX:NYR) has provided an update to the market regarding its cholesterol lowering drug program which is due to enter… Read more
“Our strategy is to advance highly optimised drug candidates towards a key value inflection point , such as an efficacy… Read more
“Looking forward, we expect Phase I studies for both the Cholesterol-Lowering and Brain Injury Programs will commence in the second… Read more
Highlights: • Cholesterol-Lowering Program advances: – New data from in vivo cholesterol study showed NYX-PCSK9i significantly increased plasma PCSK9 levels,… Read more
Nyrada Inc (ASX: NYR) is pleased to provide to shareholders and the market generally the corporate presentation that will be… Read more